Accessory Gene Regulator Polymorphism and Vancomycin Minimum Inhibitory Concentration in Methicillin-Resistant Staphylococcus aureus
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia with a vancomycin minimum inhibitory concentration (MIC) of 2 μg/mL presents a high rate of therapeutic failure in response to vancomycin. In addition, polymorphism in accessory gene regulator (agr) is associated with vancomycin therapeutic effects. The association between agr polymorphism and vancomycin MICs was investigated in MRSA isolates. Methods: Agr group-specific PCR was conducted on 118 MRSA bloodstream isolates. Vancomycin susceptibility tests were conducted, while E-test GRD (bioMérieux SA, France) was used to detect heterogeneous vancomycin-intermediate S. aureus (hVISA). Results: Of the 118 MRSA isolates, 59 (50.0%), 43 (36.4%), and 10 (8.5%) isolates belonged to agr group I, II, and III, respectively. Six isolates could not be classified. Twenty-six, 73, and 19 isolates presented a vancomycin MIC of 2, 1, and 0.5 μg/mL, respectively. Nine (34.6%), 14 (53.8%), and 2 (7.7%) isolates with MICs of 2 μg/mL belonged to agr group I, II, and III, respectively. Thirty-seven (50.6%), 26 (35.6%), and 6 (8.2%) isolates with MICs of 1 μg/mL belonged to agr group I, II, and III, respectively. Thirteen (68.4%), 3 (15.8%), and 2 (10.5%) isolates with MICs of 0.5 μg/mL belonged to agr group I, II, and III, respectively. The agr group II presented more isolates with MIC of 2 μg/mL (32.6%) than the agr non-group II (16%). Four isolates tested positive for hVISA. Three of them belonged to agr group II. Conclusions: MRSA isolates with vancomycin MIC of 2 μg/mL were more common in agr group II than in agr non-group II.
Abstract
Background: Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia with a vancomycin minimum inhibitory concentration (MIC) of 2 μg/mL presents a high rate of therapeutic failure in response to vancomycin. In addition, polymorphism in accessory gene regulator (agr) is associated with vancomycin therapeutic effects. The association between agr polymorphism and vancomycin MICs was investigated in MRSA isolates. Methods: Agr group-specific PCR was conducted on 118 MRSA bloodstream isolates. Vancomycin susceptibility tests were conducted, while E-test GRD (bioMérieux SA, France) was used to detect heterogeneous vancomycin-intermediate S. aureus (hVISA). Results: Of the 118 MRSA isolates, 59 (50.0%), 43 (36.4%), and 10 (8.5%) isolates belonged to agr group I, II, and III, respectively. Six isolates could not be classified. Twenty-six, 73, and 19 isolates presented a vancomycin MIC of 2, 1, and 0.5 μg/mL, respectively. Nine (34.6%), 14 (53.8%), and 2 (7.7%) isolates with MICs of 2 μg/mL belonged to agr group I, II, and III, respectively. Thirty-seven (50.6%), 26 (35.6%), and 6 (8.2%) isolates with MICs of 1 μg/mL belonged to agr group I, II, and III, respectively. Thirteen (68.4%), 3 (15.8%), and 2 (10.5%) isolates with MICs of 0.5 μg/mL belonged to agr group I, II, and III, respectively. The agr group II presented more isolates with MIC of 2 μg/mL (32.6%) than the agr non-group II (16%). Four isolates tested positive for hVISA. Three of them belonged to agr group II. Conclusions: MRSA isolates with vancomycin MIC of 2 μg/mL were more common in agr group II than in agr non-group II.
참고문헌 (26)
- Clinical and Laboratory Standards Institute, "Performance standards for antimicrobial susceptibility testing. Twenty third Informational supplement, M100-S23", Clinical and Laboratory Standards Institute, ~ (2013)
- Appelbaum PC, "Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA)", Int J Antimicrob Agents, 30, pp.398~408 (2007)
- Zhuo C, "Glycopeptide minimum inhibitory concentration creep among meticillin-resistant Staphylococcus aureus from 2006-2011 in China", Int J Antimicrob Agents, 41, pp.578~581 (2013)
- Moise PA, "Vancomycin in vitrobactericidal activity and its relationship to efficacy in clearance ofmethicillin-resistant Staphylococcus aureus bacteremia", AntimicrobAgents Chemother, 51, pp.2582~2586 (2007)
- Lodise TP, "Relationship between vancomycin MIC and failure among patientswith methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin", Antimicrob Agents Chemother, 52, pp.3315~3320 (2008)
- Swenson JM, "Accuracy of commercial and reference susceptibility testing methods for detecting vancomycin-intermediate Staphylococcus aureus", J ClinMicrobiol, 47, pp.2013~2017 (2009)
- Shopsin B, "Prevalence of agr specificity groups among Staphylococcus aureus strains colonizing children and their guardians", J ClinMicrobiol, 41, pp.456~459 (2003)
- Moise-Broder PA, "Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy", Clin Infect Dis, 38, pp.1700~1705 (2004)
- Sakoulas G, "Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin", Antimicrob Agents Chemother, 46, pp.1492~1502 (2002)
- Schweizer ML, "Increased mortality with accessory gene regulator (agr) dysfunction in Staphylococcus aureus among bacteremic patients", Antimicrob Agents Chemother, 55, pp.1082~1087 (2011)
- Falagas ME, "Heteroresistance: a concern of increasing clinical significance?", ClinMicrobiol Infect, 14, pp.101~104 (2008)
- Khatib R, "Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia", J AntimicrobChemother, 66, pp.1594~1599 (2011)
- Wootton M, "Evidence for reduction in breakpoints used to determine vancomycin susceptibility in Staphylococcus aureus", Antimicrob Agents Chemother, 49, pp.3982~3983 (2005)
- Murakami K, "Identification of methicillin-resistant strains of staphylococci by polymerase chain reaction", J ClinMicrobiol, 29, pp.2240~2244 (1991)
- Verdier I, "Staphylococcus aureus isolates with reduced susceptibility to glycopeptides belong to accessory gene regulator group I or II", AntimicrobAgents Chemother, 48, pp.1024~1027 (2004)
- Yusof A, "Evaluation of a new Etestvancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA", J ClinMicrobiol, 46, pp.3042~3047 (2008)
- van Hal SJ, "Methicillin-resistant Staphylococcus aureus vancomycin susceptibility testing: methodology correlations, temporal trends and clonal patterns", J AntimicrobChemother, 66, pp.2284~2287 (2011)
- van Leeuwen W, "Population studies of methicillin-resistant and -sensitive Staphylococcus aureus strains reveal a lack of variability in the agr D gene, encoding a staphylococcal autoinducer peptide", J Bacteriol, 182, pp.5721~5729 (2000)
- Strommenger B, "Obvious lack of association between dynamics of epidemic methicillin-resistant Staphylococcus aureus in central Europe and agr specificity groups", Eur J ClinMicrobiol Infect Dis, 23, pp.15~19 (2004)
- Goerke C, "Evaluation of intraspecies interference due to agr polymorphism in Staphylococcus aureus during infection and colonization", J Infect Dis, 188, pp.250~256 (2003)
- 윤희정, "Accessory Gene Regulator Group Polymorphisms in Methicillin-Resistant Staphylococcus aureus: An Association with Clinical Significance", Yonsei Medical Journal, 48(2), pp.176~183 (2007), 연세대학교의과대학
- Maor Y, "Molecular features of heterogeneous vancomycin-intermediate Staphylococcus aureus strains isolated from bacteremic patients", BMC Microbiol, 9, pp.189~ (2009)
- Fowler VGJr, "Persistent bacteremia due to methicillin-resistant Staphylococcus aureus infection is associated with agr dysfunction and low-level in vitro resistance to thrombin-induced platelet microbicidal protein", J Infect Dis, 190, pp.1140~1149 (2004)
- Charles PG, "Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus", Clin Infect Dis, 38, pp.448~451 (2004)
- van Hal SJ, "Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates", Antimicrob Agents Chemother, 55, pp.405~410 (2011)
- Musta AC, "Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years", J ClinMicrobiol, 47, pp.1640~1644 (2009)